Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase III, randomized, controlled trial (esteem 1)

Authors
Category Primary study
ConferenceJournal of the European Academy of Dermatology and Venereology
Year 2013
This article has no abstract
Epistemonikos ID: 25c5608ab5b18baf1d167f144a75d064f436dda9
First added on: Apr 30, 2026